The medicinal chemistry of novel H3 antagonists

Inflammation Research

Volumn 53, Issue SUPPL. 1, 2004, Pages

  Cowart, M ^a   Faghih, R ^a   Gfesser, G ^a   Curtis, M ^a   Pratt, J K ^a   Bennani, Y ^a   Fox, G B ^a   Esbenshade, T A ^a   Hancock, A A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; BENZOFURAN DERIVATIVE; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; N METHYLHISTAMINE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; BINDING AFFINITY; BLOOD BRAIN BARRIER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG SELECTIVITY; DRUG STRUCTURE; NONHUMAN; PHARMACOPHORE; RADIOASSAY; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELLS, CULTURED; CEREBRAL DECORTICATION; HISTAMINE ANTAGONISTS; HUMANS; RATS; RECEPTORS, HISTAMINE H3;

EID: 1642299838     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-003-0333-2     Document Type: Conference Paper

References (8)

1. 3 receptor agonists and antagonists. TiPS 1998; 19: 177-83.
2. 3 receptor and its ligands. In King FD, Oxford AW, eds. Prog Med Chem Elsevier Sci 2001; 279-309.
3. 450 enzymes. Pharmacology 2002; 66: 128-35.
4. 3 receptor antagonists. Arch Pharm Pharm Med Chem 1998; 331: 395-404.
5. 3 receptor antagonist of high oral in vivo potency with 4-(ω-(arylalkyloxy)alkyl)-1H-imidazole structure. Arch Pharm Pharm Med Chem 1998; 331: 211-8.
6. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2003; 45: 2615-23.
7. Esbenshade TA, Hancock AA. Characterization of histaminergic receptors, in Current Protocols of Pharmacology. New York: John Wiley & Sons 2000; Ch. 1.19.1.
8. 3 receptor ligands. Bioorg Med Chem Lett 2002; 12: 3077-9.